3.4.22.B49: cathepsin L1
This is an abbreviated version!
For detailed information about cathepsin L1, go to the full flat file.
Word Map on EC 3.4.22.B49
-
3.4.22.B49
-
cathepsins
-
fasciola
-
hepatica
-
fluke
-
fasciolosis
-
metacercariae
-
helminth
-
gigantica
-
medicine
-
excysted
-
trematode
-
excretory-secretory
-
immunodiagnosis
-
agriculture
-
mimotopes
-
diagnostics
- 3.4.22.B49
- cathepsins
- fasciola
- hepatica
- fluke
-
fasciolosis
-
metacercariae
-
helminth
- gigantica
- medicine
-
excysted
-
trematode
-
excretory-secretory
-
immunodiagnosis
- agriculture
-
mimotopes
- diagnostics
Reaction
clear preference for Arg at P1 position (Lys, Glu, Thr, and Met are less efficient). FheCL1 shows distinct preference for hydrophobic amino acids in the P2, Leu is favored. Cathepsin L1 can accommodate Pro in the P2 position, but less efficiently than cathepsin L2. FheCL1 produces clear degradation fragments from collagen =
Synonyms
cat-L1H, cathepsin L1, cathepsin L1 cysteine protease, cathepsin L1 protease, cathepsin L1 proteinase, cathepsin L1g, cathepsin L1H, CatL1, CgCTSL1, CGI_10027418, CL1, CPFhW, CTSL1, cysteine proteinase 3, Da-CTSL1, FgCatL1H, FhCL1, FheCL1, FhpCL1
ECTree
Advanced search results
Application
Application on EC 3.4.22.B49 - cathepsin L1
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
agriculture
diagnostics
medicine
-
screening of cathepsin L1/cathepsin L2 mimotopes and use of an M13 phage random 12-mers peptide library to evaluate their immunogenicity in sheep. Immunization of sheep with clones showing positive reactivity to rabbit cathepsin L1/L2 antiserum results in decrease in worm burdens after challenge. A significant reduction in worm size and burden is observed for those sheep immunized with clone 1. Animals receiving clone 20, show a significant reduction in egg output. Immunization induces a reduction of egg viability ranging from 58% to 82%. Vaccinated animals produce clone-specific antibodies which are boosted after challenge with metacercariae of Fasciola hepatica
agriculture
-
vaccination of rats with recombinant zymogen and subsequent challenge with fasciola hepatica metercercariae. Vaccination results in significantly smaller and fewer flukes than in controls
a monoclonal antibody (MoAb) against recombinant Fasciola gigantica cathepsin L1H (rFgCatL1H) is produced by hybridoma technique using spleen cells from BALB/c mice immunized with recombinant proFgCatL1H (rproFgCatL1H). This MoAb is an immunoglobulin (Ig)G1 with kappa light chain isotype. The MoAb reacts specifically with rproFgCatL1H, the native FgCatL1H at a molecular weight (MW) 38-48 kDa in the extract of whole body (WB) of metacercariae and newly excysted juvenile (NEJ) and cross-reacted with rFgCatL1 and native FgCatLs at MW 25 to 28 kDa in WB of 2- and 4-week-old juveniles, adult, and adult excretory-secretory (ES) fractions by immunoblotting and indirect ELISA. It does not cross-react with antigens in WB fractions from other parasites. FgCatL1H and its MoAb may be used for immunodiagnosis of both early and late fasciolosis in ruminants and humans
diagnostics
analysis of the diagnostic values of the three different clades of cathepsin Ls, FhCL1, FhCL2, and FhCL5, from adult flukes in an ELISA, test of sera from sheep and cattle naturally infected with Fasciola hepatica, of cross-reactive antibodies, overview. For sheep sera, the sensitivity is 100% for the three rFhpCLs, while for cattle sera, the highest sensitivity is obtained using rFhpCL2 (97%), being equal for both rFhpCL1 and rFhpCL5 (87.9%), after adjusting cut-offs for maximum specificity
diagnostics
design and synthesis of a new peptide derived from Fasciola gigantica cathepsin L1 with potential application in serodiagnosis of fascioliasis via ELISA, overview. Cathepsin L1 as antigen for serodiagnosis of animal fasciolosis
diagnostics
design and synthesis of a new peptide derived from Fasciola gigantica cathepsin L1 with potential application in serodiagnosis of fascioliasis via ELISA, overview. Cathepsin L1 as antigen for serodiagnosis of animal fasciolosis
diagnostics
recombinant proFgCatL1H protein expressed from Pichia pastoris is mixed with Freund's adjuvants and used to subcutaneously immunize mice, the mice are then challenged with metacercariae of Fasciola gigantica. The percentage of worm protection in the rproFgCatL1H-vaccinated mice compared to the non-immunized and adjuvant control mice are approximately 62.7% and 66.1%, respectively. Anti-rproFgCatL1H antisera collected from vaccinated mice react specifically with rproFgCatL1H and other cathepsin L isoforms of Fasciola gigantica, but the antibodies do not crossreact with antigens from other trematode and nematode parasites, including Eurytrema pancreaticum, Opisthorchis viverrini, Fischoederius cobboldi, Cotylophoron cotylophorum, Gigantocotyle explanatum, Paramphistomum cervi, and Setarialabiato papillosa
-
potential in the development of first generation liver fluke vaccines. Vaccine trials in both sheep and cattle with purified native FheCL1 and FheCL2 show that the enzymes can induce protection, ranging from 33-79%, to experimental challenge with metacercariae of Fasciola hepatica, and very potent anti-embryonation/hatch rate effects that would block parasite transmission
medicine
-
diagnostic ability to detect human IgG antibodies against Fasciola gigantica cathepsin L1 by peptide-based ELISA, serodiagnosis of human fascioliasis, which is rapid, cheap and easy to produce
medicine
the cathepsin L1 gene may be used for DNA vaccination, recombinant protein derived from the gene can be used for serological diagnostics against Fasciola hepatica in Turkey
medicine
-
enteral vaccination of rats against Fasciola hepatica using recombinant cysteine proteinase (cathepsin L1). The mature CPFhW protein is the enzyme secreted by Fasciola hepatica with which the host organism has contact. This can explain why immunisation with this antigen resultes in best protection in challenged animals, especially in comparison to the immature form of the CPFhW protein. Substantial protection can be obtained when the antigen is given with food. Oral administration of the antigen does not lead to decreasing of the level of protection compared with intragastric administration
medicine
-
cattle can be protected against a natural infection of Fasciola hepatica by vaccination with recombinant cathepsin L1
medicine
mice immunized with recombinant CL1 show a decrease of 21.8% in Schistosoma mansoni burden
medicine
a leucine aminopeptidase-cathepsin L1 chimeric protein may be used as a diagnostic tool for detection of antibodies against Fasciola hepatica in bovine sera and as an immunogen to induce protection against bovine fasciolosis
medicine
a monoclonal antibody (MoAb) against recombinant Fasciola gigantica cathepsin L1H (rFgCatL1H) is produced by hybridoma technique using spleen cells from BALB/c mice immunized with recombinant proFgCatL1H (rproFgCatL1H). This MoAb is an immunoglobulin (Ig)G1 with kappa light chain isotype. The MoAb reacts specifically with rproFgCatL1H, the native FgCatL1H at a molecular weight (MW) 38-48 kDa in the extract of whole body (WB) of metacercariae and newly excysted juvenile (NEJ) and cross-reacted with rFgCatL1 and native FgCatLs at MW 25 to 28 kDa in WB of 2- and 4-week-old juveniles, adult, and adult excretory-secretory (ES) fractions by immunoblotting and indirect ELISA. It does not cross-react with antigens in WB fractions from other parasites. FgCatL1H and its MoAb may be used for immunodiagnosis of both early and late fasciolosis in ruminants and humans
medicine
recombinant proFgCatL1H protein expressed from Pichia pastoris is mixed with Freund's adjuvants and used to subcutaneously immunize mice, the mice are then challenged with metacercariae of Fasciola gigantica. The percentage of worm protection in the rproFgCatL1H-vaccinated mice compared to the non-immunized and adjuvant control mice are approximately 62.7% and 66.1%, respectively. The levels of IgG1 and IgG2a in the immune sera are shown to be strongly correlated with the numbers of worm recovery, and the correlation coefficient is higher for IgG1. The levels of serum aspartate amino-transferase and alanine transaminase are significantly lower in the sera of rproFgCatL1H-vaccinated mice than in the infected control mice indicating a lower degree of liver damage
medicine
vaccination of mice by subcutaneous injection with recombinant proFgCatL1 and recombinant mature FgCatL1 combined with Freund's adjuvant. Two weeks after the second boost, mice are infected with 15 metacercariae by the oral route. The level of protection of rproFgCatL1 and rmatFgCatL1 vaccines is estimated to be 39.1-41.7% and 44.9-47.2% when compared with non vaccinated-infected and adjuvant-infected controls, respectively. Antibodies in the immune sera of vaccinated mice are shown by immunoblotting to react with the native FgCatL1 in the extract of newly excysted juveniles (NEJ), 4-week-old juveniles, and the excretory-secretory products of 4 week-old juveniles. rFgCatL1 has a potential as a vaccine candidate against Fasciola gigantica in mice, and might also be effective in ruminants